KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Payables (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Payables for 17 consecutive years, with $130.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables rose 5.51% to $130.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $130.3 million, a 5.51% increase, with the full-year FY2025 number at $130.3 million, up 5.51% from a year prior.
  • Payables was $130.3 million for Q4 2025 at Bio-Rad Laboratories, roughly flat from $130.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $161.5 million in Q1 2023 to a low of $103.2 million in Q1 2024.
  • A 5-year average of $136.4 million and a median of $138.1 million in 2021 define the central range for Payables.
  • Peak YoY movement for Payables: plummeted 75.75% in 2021, then soared 34.74% in 2025.
  • Bio-Rad Laboratories' Payables stood at $142.4 million in 2021, then dropped by 4.86% to $135.5 million in 2022, then increased by 7.08% to $145.1 million in 2023, then decreased by 14.89% to $123.5 million in 2024, then increased by 5.51% to $130.3 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Payables are $130.3 million (Q4 2025), $130.1 million (Q3 2025), and $140.6 million (Q2 2025).